grant
Efficacy and mechanisms of anti-IFN drugs in AGS treatment
Organization UNIVERSITY OF PITTSBURGH AT PITTSBURGHLocation PITTSBURGH, UNITED STATESPosted 1 Feb 2024Deadline 31 Jan 2029
NIHUS FederalResearch GrantFY2025Acquired brain injuryAicardi Goutieres syndromeAnimal ModelAnimal Models and Related StudiesBloodBlood Reticuloendothelial SystemBody TissuesBrainBrain DiseasesBrain DisordersBrain InflammationBrain InjuriesBrain Nervous SystemCREE ENCEPHALITISCRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCas nuclease technologyCell Communication and SignalingCell SignalingCerebrospinal FluidChronic small plaque psoriasisClinicalClinical TrialsClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyControlled Clinical TrialsDNA mutationDataDeath RateDevelopmentDiscoid psoriasisDiseaseDisease OutcomeDisorderDouble-Blind MethodDouble-Blind StudyDouble-BlindedDouble-Masked MethodDouble-Masked StudyDrugsEPH- and ELK-Related Tyrosine KinaseEPH-and ELK-Related KinaseEncephalitisEncephalonEncephalon DiseasesEncephalopathiesEncephalopathy with intracranial calcification and chronic lymphocytosis of cerebrospinal fluidEncephalopathy, familial infantile, with calcification of basal ganglia and chronic cerebrospinal fluid lymphocytosisEnrollmentEphrin Type-A Receptor 8Ephrin Type-A Receptor 8 PrecursorExhibitsFDA approvedGene ExpressionGenesGeneticGenetic ChangeGenetic defectGenetic mutationIFNIFN activationIFN-GammaIFN-gIFN-γIFNGIFNγImmuneImmune Cell ActivationImmune InterferonImmunesInflammatoryInflammatory ResponseInterferon ActivationInterferon GammaInterferon Type IInterferon Type IIInterferonsIntracellular Communication and SignalingIntracranial CNS DisordersIntracranial Central Nervous System DisordersJAK kinaseJAK1JAK1 geneJAK1 proteinJAK1AJak1 kinaseJanus kinaseJanus kinase 1MedicationMedicineMental disabilityMethodsMiceMice MammalsModelingMolecularMorphologyMurineMusMutant Strains MiceMutationNF-KB-Activating KinaseNF-KB-Activating Kinase NAKNucleic AcidsNummular psoriasisOrphan DiseaseOutcomePathogenesisPathologicPathologyPathway interactionsPatientsPeripheralPharmaceutical PreparationsPhenotypePlacebo ControlPlacebosPlaque psoriasisProductionProtein Tyrosine KinaseProtein Tyrosine Kinase EEKPsoriasis vulgarisPublicationsRare DiseasesRare DisorderReportingSTAT proteinSTAT1STAT1 geneSTAT91Scientific PublicationSeriesSham TreatmentSignal PathwaySignal Transducer and Activator of TranscriptionSignal TransductionSignal Transduction SystemsSignalingSiteTANK Binding Kinase TBK1TANK-binding kinase 1TestingTherapeuticTherapeutic StudiesTherapy ResearchTimeTissuesTyrosine KinaseTyrosine-Protein Kinase JAK1Tyrosine-Protein Kinase Receptor EEKTyrosine-Specific Protein KinaseTyrosylprotein Kinaseautoinflammatorybiological signal transductionbrain cellbrain damagebrain-injuredcerebral spinal fluidclinical relevanceclinically relevantcognitive disabilitycognitively disabledcomparable efficacycomparative efficacycompare efficacydetermine efficacydevelop therapydevelopmentaldrug candidatedrug efficacydrug/agenteffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy testingenrollevaluate efficacyexamine efficacygenome mutationhydroxyaryl protein kinaseimmune activationimprovedimproved outcomein vivoinfancyinfantileinhibitorinsightintervention developmentkinase inhibitorlFN-Gammamicrocephaly-chorioretinopathy syndromemodel of animalmortality ratemortality ratiomouse genomemouse modelmouse mutantmurine modelneuralneural inflammationneuroinflammationneuroinflammatorynew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetopen labelopen label studyorphan disorderpathwayphysical disabilityphysically disabledphysically handicappedplacebo controlledpre-clinicalpre-clinical studypreclinicalpreclinical studypreventpreventingpseudotoxoplasmosis syndromeresponsesham therapysmall molecular inhibitorsmall molecule inhibitorspinal fluidtherapy developmenttreatment developmenttyrosyl protein kinaseupstream kinase
Description preview
Abstract
Aicardi-Goutiéres syndrome (AGS) is a severe, often lethal genetic autoinflammatory
encephalopathy. It typically has an infantile-onset and results in progressive and profound
cognitive and physical disability. There is an urgent need to find an effective therapy for AGS, but
currently, there is no FDA-approved therapeutic approach that…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click